Mark J. Ratain to Indoles
This is a "connection" page, showing publications Mark J. Ratain has written about Indoles.
Connection Strength
0.898
-
Vemurafenib oral bioavailability: an insoluble problem. J Clin Pharmacol. 2014 Apr; 54(4):375-7.
Score: 0.411
-
Phase I trial of orally administered CEP-701, a novel neurotrophin receptor-linked tyrosine kinase inhibitor. Invest New Drugs. 2005 Jan; 23(1):31-7.
Score: 0.217
-
Intraindividual Pharmacokinetic Variability: Focus on Small-Molecule Kinase Inhibitors. Clin Pharmacol Ther. 2018 06; 103(6):956-958.
Score: 0.133
-
Two drug interaction studies of sirolimus in combination with sorafenib or sunitinib in patients with advanced malignancies. Clin Cancer Res. 2011 Apr 01; 17(7):1956-63.
Score: 0.083
-
Serum C-Telopeptide Collagen Crosslinks and Plasma Soluble VEGFR2 as Pharmacodynamic Biomarkers in a Trial of Sequentially Administered Sunitinib and Cilengitide. Clin Cancer Res. 2015 Nov 15; 21(22):5092-9.
Score: 0.028
-
Phase I study of adozelesin administered by 24-hour continuous intravenous infusion. J Natl Cancer Inst. 1994 Mar 02; 86(5):368-72.
Score: 0.026